245 related articles for article (PubMed ID: 18836451)
1. Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self.
Mohammed F; Cobbold M; Zarling AL; Salim M; Barrett-Wilt GA; Shabanowitz J; Hunt DF; Engelhard VH; Willcox BE
Nat Immunol; 2008 Nov; 9(11):1236-43. PubMed ID: 18836451
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for the presentation of tumor-associated MHC class II-restricted phosphopeptides to CD4+ T cells.
Li Y; Depontieu FR; Sidney J; Salay TM; Engelhard VH; Hunt DF; Sette A; Topalian SL; Mariuzza RA
J Mol Biol; 2010 Jun; 399(4):596-603. PubMed ID: 20417641
[TBL] [Abstract][Full Text] [Related]
3. Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy.
Zarling AL; Polefrone JM; Evans AM; Mikesh LM; Shabanowitz J; Lewis ST; Engelhard VH; Hunt DF
Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14889-94. PubMed ID: 17001009
[TBL] [Abstract][Full Text] [Related]
4. Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy.
Depontieu FR; Qian J; Zarling AL; McMiller TL; Salay TM; Norris A; English AM; Shabanowitz J; Engelhard VH; Hunt DF; Topalian SL
Proc Natl Acad Sci U S A; 2009 Jul; 106(29):12073-8. PubMed ID: 19581576
[TBL] [Abstract][Full Text] [Related]
5. Altered peptide ligands revisited: vaccine design through chemically modified HLA-A2-restricted T cell epitopes.
Hoppes R; Oostvogels R; Luimstra JJ; Wals K; Toebes M; Bies L; Ekkebus R; Rijal P; Celie PH; Huang JH; Emmelot ME; Spaapen RM; Lokhorst H; Schumacher TN; Mutis T; Rodenko B; Ovaa H
J Immunol; 2014 Nov; 193(10):4803-13. PubMed ID: 25311806
[TBL] [Abstract][Full Text] [Related]
6. The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles.
Molvi Z; Klatt MG; Dao T; Urraca J; Scheinberg DA; O'Reilly RJ
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37775115
[TBL] [Abstract][Full Text] [Related]
7. Crystal structures of HLA-A*0201 complexed with Melan-A/MART-1(26(27L)-35) peptidomimetics reveal conformational heterogeneity and highlight degeneracy of T cell recognition.
Douat-Casassus C; Borbulevych O; Tarbe M; Gervois N; Jotereau F; Baker BM; Quideau S
J Med Chem; 2010 Oct; 53(19):7061-6. PubMed ID: 20806940
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL.
Andersen MH; Bonfill JE; Neisig A; Arsequell G; Sondergaard I; Valencia G; Neefjes J; Zeuthen J; Elliott T; Haurum JS
J Immunol; 1999 Oct; 163(7):3812-8. PubMed ID: 10490979
[TBL] [Abstract][Full Text] [Related]
9. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
[TBL] [Abstract][Full Text] [Related]
10. Differential presentation of tumor antigen-derived epitopes by MHC-class I and antigen-positive tumor cells.
Held G; Neumann F; Sturm C; Kaestner L; Dauth N; de Bruijn DR; Renner C; Lipp P; Pfreundschuh M
Int J Cancer; 2008 Oct; 123(8):1841-7. PubMed ID: 18688854
[TBL] [Abstract][Full Text] [Related]
11. High-resolution structure of HLA-A*0201 in complex with a tumour-specific antigenic peptide encoded by the MAGE-A4 gene.
Hillig RC; Coulie PG; Stroobant V; Saenger W; Ziegler A; Hülsmeyer M
J Mol Biol; 2001 Jul; 310(5):1167-76. PubMed ID: 11502003
[TBL] [Abstract][Full Text] [Related]
12. Structural basis for ineffective T-cell responses to MHC anchor residue-improved "heteroclitic" peptides.
Madura F; Rizkallah PJ; Holland CJ; Fuller A; Bulek A; Godkin AJ; Schauenburg AJ; Cole DK; Sewell AK
Eur J Immunol; 2015 Feb; 45(2):584-91. PubMed ID: 25471691
[TBL] [Abstract][Full Text] [Related]
13. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
[TBL] [Abstract][Full Text] [Related]
14. A Molecular Basis for the Presentation of Phosphorylated Peptides by HLA-B Antigens.
Alpízar A; Marino F; Ramos-Fernández A; Lombardía M; Jeko A; Pazos F; Paradela A; Santiago C; Heck AJ; Marcilla M
Mol Cell Proteomics; 2017 Feb; 16(2):181-193. PubMed ID: 27920218
[TBL] [Abstract][Full Text] [Related]
15. Classical and nonclassical class I major histocompatibility complex molecules exhibit subtle conformational differences that affect binding to CD8alphaalpha.
Gao GF; Willcox BE; Wyer JR; Boulter JM; O'Callaghan CA; Maenaka K; Stuart DI; Jones EY; Van Der Merwe PA; Bell JI; Jakobsen BK
J Biol Chem; 2000 May; 275(20):15232-8. PubMed ID: 10809759
[TBL] [Abstract][Full Text] [Related]
16. HLA-A*0201-restricted CTL epitope of a novel osteosarcoma antigen, papillomavirus binding factor.
Tsukahara T; Kawaguchi S; Torigoe T; Takahashi A; Murase M; Kano M; Wada T; Kaya M; Nagoya S; Yamashita T; Sato N
J Transl Med; 2009 Jun; 7():44. PubMed ID: 19523231
[TBL] [Abstract][Full Text] [Related]
17. MHC-restricted phosphopeptides from insulin receptor substrate-2 and CDC25b offer broad-based immunotherapeutic agents for cancer.
Zarling AL; Obeng RC; Desch AN; Pinczewski J; Cummings KL; Deacon DH; Conaway M; Slingluff CL; Engelhard VH
Cancer Res; 2014 Dec; 74(23):6784-95. PubMed ID: 25297629
[TBL] [Abstract][Full Text] [Related]
18. Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides.
Kessler JH; Mommaas B; Mutis T; Huijbers I; Vissers D; Benckhuijsen WE; Schreuder GM; Offringa R; Goulmy E; Melief CJ; van der Burg SH; Drijfhout JW
Hum Immunol; 2003 Feb; 64(2):245-55. PubMed ID: 12559627
[TBL] [Abstract][Full Text] [Related]
19. Structures of native and affinity-enhanced WT1 epitopes bound to HLA-A*0201: implications for WT1-based cancer therapeutics.
Borbulevych OY; Do P; Baker BM
Mol Immunol; 2010 Sep; 47(15):2519-24. PubMed ID: 20619457
[TBL] [Abstract][Full Text] [Related]
20. Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design.
Borbulevych OY; Baxter TK; Yu Z; Restifo NP; Baker BM
J Immunol; 2005 Apr; 174(8):4812-20. PubMed ID: 15814707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
